Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Dr Ricky Frazer and Dr Rebecca Dobson

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective ( Dr Ricky Frazer and Dr Rebecca Dobson )

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory...

Dr Anthony Stein - City of Hope, Duarte, USA

$Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )$

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with...

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared...

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy...

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse...

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

$POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )$

Understanding Ghana's FDA and pharmacovigilance regulations

Ms. Priscilla Aduse-Poku

Understanding Ghana's FDA and pharmacovigilance regulations ( Ms. Priscilla Aduse-Poku )

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

More from ecancer